Holen Sie sich die Stockscreener-App
58.00
1.79%
-1.36
Schlusskurs vom Vortag:
$59.36
Offen:
$59.4
24-Stunden-Volumen:
17,277
Relative Volume:
0.04
Marktkapitalisierung:
$3.65B
Einnahmen:
$101.78M
Nettoeinkommen (Verlust:
$-259.43M
KGV:
-17.68
EPS:
-3.28
Netto-Cashflow:
$-163.06M
1W Leistung:
-2.47%
1M Leistung:
+16.15%
6M Leistung:
+53.37%
1J Leistung:
+74.49%
1-Tages-Spanne:
$58.11
$59.63
1-Wochen-Bereich:
$55.37
$60.79
52-Wochen-Spanne:
$31.52
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RYTM | 58.30 | 3.65B | 101.78M | -259.43M | -163.06M | -3.28 |
| VRTX | 446.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.20 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.50 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals Announces Five Presentations at ESPE - GlobeNewswire
Rhythm Pharma: New Drug Shows 9.6% Weight Loss in Pediatric Obesity Treatment Study | RYTM Stock News - StockTitan
Perceptive Advisors LLC's Strategic Acquisition in Rhythm Pharma - GuruFocus.com
(RYTM) Proactive Strategies - Stock Traders Daily
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock By Investing.com - Investing.com Nigeria
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock - Investing.com
Rhythm Pharmaceuticals EVP sells $4.43m in stock By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals EVP sells $4.43m in stock - Investing.com
Rhythm Pharmaceuticals Announces Publication of Results - GlobeNewswire
Rhythm Pharma's Obesity Drug Shows 83% Success in Phase 3 Trial, FDA Priority Review Set | RYTM Stock News - StockTitan
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewswire
Rhythm Pharmaceuticals Awards 15,750 RSUs to New Employees in Talent Acquisition Push | RYTM Stock News - StockTitan
PRIMECAP Management Adjusts Stake in Rhythm Pharmaceuticals - GuruFocus.com
Goldman Sachs Group Inc Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus.com
High Growth Tech Stocks Featuring Three Prominent US Companies - Simply Wall St
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 52-Week HighWhat's Next? - MarketBeat
HC Wainwright Issues Pessimistic Outlook for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock By Investing.com - Investing.com Australia
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 4,688 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock - Investing.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $69.00 - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance UK
8,594 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Creative Planning - MarketBeat
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highligh - GuruFocus.com
Earnings call: Rhythm Pharmaceuticals has reported a successful third quarter in 2024 - Investing.com India
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $64.00 at Needham & Company LLC - MarketBeat
Rhythm Pharmaceuticals CEO to Present at Major Healthcare Investor Conferences | RYTM Stock News - StockTitan
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewswire
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year HighTime to Buy? - MarketBeat
Rhythm Pharma stock soars to all-time high of $55.65 By Investing.com - Investing.com Canada
Rhythm Pharma stock soars to all-time high of $55.65 - Investing.com
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading 7.4% HigherTime to Buy? - MarketBeat
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 - The Manila Times
What's Next: Rhythm Pharmaceuticals's Earnings Preview - Benzinga
(RYTM) Investment Analysis - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Nisa Investment Advisors LLC Has $3.47 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Needham & Company LLC Reaffirms Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rhythm Pharmaceuticals Inc-Aktie (RYTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lee Jennifer Kayden | EVP, Head of North America |
Nov 11 '24 |
Sale |
66.33 |
66,861 |
4,434,882 |
972 |
| Shulman Joseph | Chief Technical Officer |
Nov 11 '24 |
Option Exercise |
12.63 |
13,281 |
167,760 |
13,281 |
| Shulman Joseph | Chief Technical Officer |
Nov 11 '24 |
Sale |
66.44 |
13,281 |
882,341 |
0 |
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):